item management s discussion and analysis of results of operations and of financial conditions general for more than years  c 
r 
bard  inc has committed its resources to creating innovative solutions to meet the needs of both health care providers and their patients 
the company is a global leader in the development  manufacture and supply of products and services to the health care industry 
bard addresses the health care opportunity through disease state management an approach that expands the focus from products and technologies to the underlying clinical condition  thereby positioning the company as an indispensable partner to the deliverers of health care 
bard is committed to developing leadership franchises within the disease states and using these strategic positions to leverage the company s growth 
after a significant divestiture and restructuring program  bard has demonstrated improved growth and profitability trends in summary results bard reported net sales of  million  up over net sales of ongoing products of million 
the company demonstrated substantial sales growth in each of its four product groups vascular  urology  oncology and surgery 
bard reported net income of million or of diluted earnings per share in compared with net income of million or of diluted earnings per share in both years earnings include one time items 
without these one time items  diluted earnings per share was in and in  a increase 
net of one time items  bard also significantly increased its margin of net income to net sales to from in results of operations vs 
net sales for totaled  million 
bard reported net sales for of  million  which included sales from products which were divested during that year 
on an ongoing product basis  net sales represent a increase over net sales of million 
price reductions and the impact of a stronger dollar had the effect of reducing net sales by and  respectively 
sales of vascular products increased in to million 
the electrophysiology and peripheral technology franchises continued to show strong worldwide growth 
impra graft sales also displayed healthy growth in urology product group sales increased in to million 
basic drainage products experienced double digit growth  fueled by outstanding sales of the infection control foley catheter 
sales of oncology products increased in to million 
specialty access products demonstrated balanced growth worldwide  while interventional products showed particularly strong growth internationally 
sales of surgery products grew in to million  paced by the mesh product line  used primarily in hernia repair 
the product group areas discussed above represent substantially all of bard s ongoing product sales 
ii net sales by product group for the last three years in thousands are vascular urology oncology surgery other ongoing products total ongoing products divested products net sales net sales in the u 
s 
of ongoing products rose to million 
the oncology and surgery products provided the best growth 
net sales of ongoing products outside the us also increased to million  with growth demonstrated by vascular and oncology products 
for the year  a stronger dollar had the impact of reducing these sales by 
bard markets its products through direct selling organizations and selected distributors throughout the world 
the geographic breakdown of net sales of ongoing products for each of the last three years is proportioned as follows united states  europe  japan and other 
despite continued pricing pressure  cost of goods sold as a percent of net sales declined from in to in these improved results are due to the company s ongoing manufacturing restructuring programs and the divestitures of the lower margin cardiology businesses 
marketing  selling and administrative expense declined in as a percent of sales  these expenses declined to from in this reduction was attributed to the cardiology divestitures and improved efficiency in the company s sales and administration efforts 
reported research and development expense declined  due to the impact of the cardiology divestitures  however  research and development spending on non divested businesses increased in interest expense declined in due to lower average debt levels and improved operating cash flow 
please refer to note  other income expense  net  of the notes to consolidated financial statements on page ii in this report for a summary of items in this category in the last three years 
included in is a pretax charge of million for the writedown of impaired assets and million of interest income 
the company recorded one time gains in both and related to the dispositions of its cardiology product lines 
a pretax gain of million was recorded in the fourth quarter of and a pretax gain of million was recorded in the fourth quarter of please refer to note  acquisitions and dispositions  of the notes to consolidated financial statements on page ii for additional disclosure 
the effective tax rate was in and in the effective tax rate includes the impact of the gain from the disposition of the cardiology businesses  which was taxed at an effective rate of approximately 
ii net income in  bard reported net income of million or diluted earnings per share of 
excluding the impact of the after tax gain on the sale of the cardiopulmonary business of and the after tax impact of the fourth quarter writedown of impaired assets of  diluted earnings per share was 
in  bard reported net income of million or diluted earnings per share of 
excluding the impact of the after tax gain on the sale of the cardiology businesses of  the net after tax loss from one time items of and the after tax impact of the year costs of  diluted earnings per share was 
in  bard reported net income of million or diluted earnings per share of 
excluding the net after tax loss from one time items of and the after tax impact of the year costs of  diluted earnings per share was 
results of operations vs 
net sales for totaled  million  which represents a decline from the prior year mostly due to the divestiture of the cardiology businesses 
full year net sales of ongoing products were million  an increase of over comparable results 
price reductions and the impact of a stronger dollar had the effect of reducing reported net sales by and  respectively 
sales of vascular products rose in peripheral technology and electrophysiology devices showed strong worldwide growth 
urology product sales grew in the infection control foley catheter and the brachytherapy business provided the majority of the growth in this area 
sales of oncology products increased in specialty access devices showed good growth particularly in international markets 
sales of surgery products grew in  propelled by high worldwide growth of mesh products  used primarily for hernia repair 
net sales in the us of ongoing products rose to million 
the vascular and surgery products provided the best growth 
net sales of ongoing products outside the us increased to million with growth demonstrated by urology  oncology and surgery products 
global pricing pressures together with the additional expenditures related to bard s ongoing manufacturing restructuring effort increased cost of goods sold as a percent of net sales to in from in marketing  selling and administrative expense declined in as a percent of net sales  these expenses increased due to the effect of several one time items such as year functionality expenditures 
reported research and development expense declined in as a result of the sale of the cardiology businesses  while bard s spending on its ongoing products was consistent with the prior year 
ii interest expense declined in due primarily to bard s decision to utilize a portion of the proceeds from the sale of the cardiology businesses to repay short term debt 
other income expense  net  in included a net gain of million from the settlement of various patent infringement and legal claims  a charge of million for the writedown of assets primarily associated with divested businesses and a charge of million related to acquired research and development 
in  the company divested several cardiology product lines 
these transactions closed in the fourth quarter of and the company recorded a pretax gain of million 
the effective tax rate was in and in the increase in was largely the result of the sale of the cardiology businesses 
net income in  net income increased to million including a gain on the sale of the cardiology businesses and other one time items as described earlier in this review 
year functionality bard did not experience any significant internal business disruptions as a result of the calendar change to the year functionality 
to date bard has not observed any significant disruptions at either its major customers or vendors 
the company has reviewed fourth quarter sales activity and believes that there was no significant customer stocking activity related to year preparations 
the company does not believe that it will experience significant return activity or lower sales as a result of year activities 
the company s marketing  selling and administrative expense included million for it related year expenditures in  million in and million in the company anticipates that it will spend approximately  in for final system tests and retrofitting 
these incremental costs do not include existing internal resources allocated to year project efforts 
financial condition and liquidity bard s financial condition remains strong 
total debt was million at december   up from million at december  this increase was primarily the result of acquisitions of products and technologies  repurchases of common stock and additions to cash at year end to address the risk of year related liquidity constraints 
total debt to total capitalization was at december   compared to at december   while net debt  or debt less cash and short term investments to total capitalization was at december   compared to at december  shareholders investment was impacted in by the repurchase of million of common stock 
the company has a million syndicated  committed credit facility with a group of banks 
the company made no borrowings under this credit facility in the facility expires may  this facility supports a commercial paper program of million 
the company borrows actively under this program 
ii in addition to the million committed credit facility  bard maintains uncommitted credit lines with banks for short term cash needs and these lines were used as needed during the last three years 
at december   the unused uncommitted lines of credit totaled million 
cash provided from operations continued to be the company s primary source of funds to finance operating needs  capital expenditures and dividend payments 
the company believes it could borrow adequate funds at competitive terms and rates  should it be necessary 
this overall financial strength gives bard sufficient financing flexibility 
total cash outlays made for the purchase of businesses  patents  trademarks  purchase rights  and other related items were approximately million in  million in  and million in the majority of these investments were for intangible assets  reflecting the premium over book value for these purchases 
the majority of the cash outlays were financed with additional debt  with the balance coming from cash from operations 
periodically  the company purchases its common stock in the open market to replace shares issued under various employee stock plans 
in connection with the announced sale of the cardiology businesses  the board of directors in july of authorized the purchase from time to time of up to million shares of common stock 
total shares purchased were  in   in  and  in foreign currency risk the company periodically enters into foreign exchange contracts and options to reduce its exposure to fluctuations in currency values 
contracts have been exclusively for the forward purchase of  and options in  currencies in which the company has known or anticipated payments 
monetary assets of the company held in foreign currencies have relatively short maturities and are denominated in currencies that have not experienced wide short term fluctuations in their equivalent us dollar values 
please refer to note  short term borrowings and long term debt  of the notes to consolidated financial statements on page ii of this report for current details of the company s foreign exchange contracts 
on january   the eleven member countries of the european union began the transition to a common currency  the euro 
these participating countries expect the euro transition to be completed by july the company is currently evaluating potential euro related issues including pricing marketing strategy  conversion of computer systems  existing contracts and currency risk in the participating countries 
at the present time  management does not believe the euro conversion will have a materially adverse impact on our business 
legal proceedings for a discussion of pending legal proceedings and related matters  please see note  commitments and contingencies  of the notes to consolidated financial statements on page ii acquisitions and dispositions for information on the company s acquisitions and dispositions of businesses  please see note  acquisitions and dispositions  of the notes to consolidated financial statements on page ii ii cautionary statement regarding forward looking information certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally  including statements regarding the use of net proceeds from the sale of the company s cardiology businesses  statements regarding cost savings from restructuring and statements regarding the company s future performance  may contain forward looking statements as defined in the private securities litigation reform act of because actual results are affected by risks and uncertainties  the company cautions investors that actual results may differ materially from those expressed or implied 
factors that could cause the actual results to differ materially from expected and historical results include  but are not limited to health care industry consolidation resulting in customer demands for price concessions and contracts that are more complex and have longer terms  competitive factors  including competitors attempts to gain market share through aggressive marketing programs  the development of new products or technologies by competitors and technological obsolescence  reduction in medical procedures performed in a cost conscious environment  the lengthy approval time by the fda or other government authorities to clear medical devices for commercial release  unanticipated product failures  legislative or administrative reforms to the us medicare and medicaid systems or other us reimbursement systems in a manner that would significantly reduce reimbursements for procedures using the company s medical devices  the acquisition of key patents by competitors that would have the effect of excluding the company from new market segments  the uncertainty of whether increased research and development expenditures will result in increased sales  unpredictability of existing and future litigation including litigation regarding product liability and intellectual property  government actions or investigations affecting the industry in general or the company in particular  future difficulties obtaining product liability insurance on reasonable terms  efficacy or safety concerns with respect to marketed products  whether scientifically justified or not  that may lead to product recalls  withdrawals or declining sales  uncertainty related to tax appeals and litigation  future difficulties obtaining necessary components used in the company s products and or price increases from the company s suppliers of critical components  economic factors over which the company has no control  including changes in inflation  foreign currency exchange rates and interest rates  other factors over which the company has no control  including earthquakes  floods  fires and explosions  risks associated with maintaining and expanding international operations  and the risk that the company may not achieve manufacturing or administrative efficiencies as a result of the company s restructuring  the integration of acquired businesses or divestitures 
ii 
